These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35530332)

  • 1. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer.
    Liu C; Wang P; Sun Y; Dou X; Hu X; Zou W; Sun Y; Hu Q; Yue J
    Front Oncol; 2022; 12():756811. PubMed ID: 35530332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer.
    Liu C; Li X; Li A; Zou W; Huang R; Hu X; Yu J; Zhang X; Yue J
    J Immunol Res; 2022; 2022():9621466. PubMed ID: 35419462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
    Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints.
    Ari A; Sevik H; Sevinc MM; Tatar C; Buyukasik K; Surel AA; Idiz UO
    Cancer Biother Radiopharm; 2024 Apr; 39(3):247-254. PubMed ID: 38010745
    [No Abstract]   [Full Text] [Related]  

  • 5. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
    Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
    Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.
    Odagiri N; Hai H; Thuy LTT; Dong MP; Suoh M; Kotani K; Hagihara A; Uchida-Kobayashi S; Tamori A; Enomoto M; Kawada N
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
    Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
    Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Treatment Response of Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Amide Proton Transfer MRI Combined With Diffusion-Weighted Imaging.
    Chen W; Mao L; Li L; Wei Q; Hu S; Ye Y; Feng J; Liu B; Liu X
    Front Oncol; 2021; 11():698427. PubMed ID: 34277445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis.
    Li W; Xia Y; Yang J; Guo H; Sun G; Sanyal AJ; Shah VH; Lou Y; Zheng X; Chalasani N; Yu Q
    Hepatol Commun; 2020 Apr; 4(4):588-605. PubMed ID: 32258953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
    Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
    Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
    Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Treatment T2-WI Based Radiomics Features for Prediction of Locally Advanced Rectal Cancer Non-Response to Neoadjuvant Chemoradiotherapy: A Preliminary Study.
    Petresc B; Lebovici A; Caraiani C; Feier DS; Graur F; Buruian MM
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI Tumor Regression Grade Combined with T2-Weighted Volumetry May Predict Histopathological Response in Locally Advanced Rectal Cancer following Neoadjuvant Chemoradiotherapy-A New Scoring System Proposal.
    Jankovic A; Kovac JD; Dakovic M; Mitrovic M; Saponjski D; Milicevic O; Djuric-Stefanovic A; Barisic G
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
    Wang J; Liu J; Wang J; Wang S; Li F; Li R; Liu P; Li M; Wang C
    Cancer Cell Int; 2022 Mar; 22(1):117. PubMed ID: 35292026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study.
    Liang Y; Zhu Y; Lin H; Zhang S; Li S; Huang Y; Liu C; Qu J; Liang C; Zhao K; Li Z; Liu Z
    BMC Cancer; 2021 Jun; 21(1):729. PubMed ID: 34172021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Zheng Z; Wang X; Huang Y; Lu X; Chi P
    Colorectal Dis; 2020 Dec; 22(12):2068-2077. PubMed ID: 32936987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.